Midokalm-Richter 100 mg / ml + 2.5 mg / ml 1 ml , 5 pcs.

Active substances:

tolperisone hydrochloride 100 mg,

lidocaine hydrochloride 2.5 mg;

Excipients:

methyl paraben

diethylene glycol monoethyl ether,

water d / and;

Midokalm - muscle relaxant.

Pharmacodynamics

Muscle relaxant central action. The mechanism of action is not fully understood. It has a membrane-stabilizing, local anesthetic effect, inhibits the conduction of impulses in primary afferent fibers and motor neurons, which leads to blocking of spinal mono- and polysynaptic reflexes.

It is also likely that it slows down the release of mediators by inhibiting the entry of Ca ²⁺  into synapses. In the brain stem eliminates the facilitation of the excitation along the reticulospinal path.

Enhances peripheral blood flow regardless of the effect of the central nervous system. In the development of this effect, the weak antispasmodic and adrenoblocking effect of tolperisone plays a role.

Pharmacokinetics

After oral administration, tolperisone is well absorbed from the digestive tract. C _{max is}  achieved after 0.5–1 h, bioavailability is about 20%.

Tolperisone is metabolized in the liver and kidneys. It is excreted in the urine in the form of metabolites (more than 99%). The pharmacological activity of metabolites is unknown.

• treatment of pathologically increased muscle tone and spasms of striated muscles resulting from organic diseases of the central nervous system (pyramidal lesions, multiple sclerosis, cerebral stroke, myelopathy, encephalomyelitis);
• treatment of increased tone and muscle spasms, muscle contractures accompanying diseases of the organs of motion (including spondylosis, spondylitis, cervical and lumbar syndromes, arthrosis of large joints);
• rehabilitation treatment after orthopedic and traumatological operations;
• in the combination therapy of obliterating vascular diseases (atherosclerosis obliterans, diabetic angiopathy, thromboangiitis obliterans, Raynaud's disease, diffuse scleroderma), diseases arising from vascular innervation disorders (acrocyanosis, intermittent angioneurotic dysbasia);
• Little's disease (cerebral palsy) and other encephalopathies accompanied by muscular dystonia.

• hypersensitivity to any of the components of the drug;
• myasthenia gravis;
• children under 3 years old.

Muscle weakness, headache, arterial hypotension, nausea, vomiting, abdominal discomfort. With a decrease in dose, side effects usually disappear.

In rare cases, allergic reactions occur (skin itching, erythema, urticaria, angioedema, anaphylactic shock, bronchospasm).

100 mg 2 times a day is administered to adults i / m or i.v. (slowly) 100 mg once a day.

injection